According to the most recent Form 13F that the company has filed with the SEC, Tudor Investment Corporation and its affiliates grew their holdings in Geron Company (NASDAQ: GERN) by a staggering 346.6% during the third quarter.
As a result of the company’s purchase of an additional 86,633 shares of stock in the biopharmaceutical company during the period in question, it now has a total of 111,625 shares of stock in the biopharmaceutical company in its possession.
The most recent report that Tudor Investment Corp.
Et al. has filed with the SEC indicates that the company possesses an interest in Geron valued at $261,000.
Recent analyst reports have devoted significant space to GERN’s in-depth analysis.
B. Riley stated their intention to increase their price target for Geron shares from $4.00 to $5.00 in a research note that was made public on January 9 and was published online. Needham & Company LLC increased their price target on Geron stock from $3.00 to $4.00 and rated the company as a “buy” in a research note published on Monday, January 9.
The company also received a “buy” rating from Needham & Company LLC On January 26, StockNews.com changed its recommendation for Geron’s shares to “sell,” indicating a lower level of interest in the company’s stock. Wedbush Investment Research upgraded the stock of Geron from an “underperform” rating to an “outperform” rating in a research report published on Wednesday, January 4.
There have been five buy ratings placed on the stock by equity research analysts, whereas there has only been one sell rating placed on the company’s shares.
According to information from Bloomberg.com, the company is currently rated as having a consensus “Moderate Buy” recommendation, and its average price target is $5.50.
This recommendation indicates that investors should purchase the company’s stock.
Recently, several institutional investors have adjusted the proportion of the company’s stock that they own, either increasing or decreasing it.
During the third quarter, Cubist Systematic Strategies LLC made a fresh investment of $169,000 in Geron.
This was the company’s third investment in the company.
During the third quarter of 2018, OmniStar Financial Group INC made a fresh investment of $25,000 in Geron.
Through the third quarter, Renaissance Technologies LLC achieved a 10.7% increase in the proportion of Geron stock that it holds within its portfolio.
The period included the purchase of an additional 22,500 shares, bringing the total number of shares owned by Renaissance Technologies LLC in the biopharmaceutical company to 233,700.
These shares have a total value of $547,000 and were purchased during the period in question.
Ergoteles LLC spent approximately 72,000 dollars during the third quarter to purchase a new interest in Geron.
And finally, during the third quarter, MetLife Investment Management LLC increased the percentage of Geron stock it held in its portfolio by 40.1%.
This was the company’s third consecutive quarter of growth.
As a result of the purchase of 54,876 additional shares during the period in question, MetLife Investment Management LLC now owns 191,615 shares in the biopharmaceutical business.
These shares are currently valued at a total of $448,000, thanks to the acquisition of these shares. Shares of the company are currently owned by hedge funds and other types of institutional investors, who collectively account for 49.75% of the total.
In other news, on February 8, the company’s Chief Financial Officer, Olivia Kyusuk Bloom, completed a transaction that involved the sale of 400,000 shares of the ownership of the business.
A total of $1,232,000.00 was received for the sale of the shares, totaling an average price of $3.08 per share.
The chief financial officer has an investment in the company that is equal to 74,588 shares, and the value of that investment is approximately $229,731.04.
The SEC’s website can access information regarding the sale submitted to the Securities and Exchange Commission.
Additionally, on February 9, the company’s Chief Operating Officer (COO), Andrew J. Grethlein, sold 384,719 of the company’s shares of stock.
The price per share was $3.03 on average when the shares were sold, which resulted in a total sale price of $1,165,698.57 being realized.
The transaction was made public through a filing that was made with the SEC, which can be located on the website of the SEC. On the same day, February 8, the company’s Chief Financial Officer, Olivia Kyusuk Bloom, sold 400,000 of the company’s shares.
The price received for each share was an average of $3.08, and the total amount received from the sale of the stock was $1,232,000.00.
The personal investment portfolio of the chief financial officer currently contains 74,588 shares of the company. Considering their current market price of $229,731.04, these shares have a value of $229,731.04.
Disclosures related to the sale might be found in this website section.
Business insiders have sold 1,231,385 shares over the past three months and ninety days, bringing in a total of $3,751,097 in revenue due to their actions.
The company’s current management and employees collectively own 6% of the company’s shares.
When trading started on Friday, the price of a share of GERN stock was $2.68.
This price remained unchanged throughout the day. Geron Company hit an all-time low of $1.01 during the past year while reaching an all-time high of $3.84 during
Discussion about this post